Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Bresnik, MD
Gilead Sciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Mobile, Alabama, United States
- Facility name not stated
Phoenix, Arizona, United States
- Facility name not stated
Little Rock, Arkansas, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
Hartford, Connecticut, United States
- Facility name not stated
Wilmington, Delaware, United States
- Facility name not stated
Jacksonville, Florida, United States
- Facility name not stated
Miami, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Glenview, Illinois, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Worcester, Massachusetts, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Minneapolis, Minnesota, United States
- Facility name not stated
St Louis, Missouri, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Morristown, New Jersey, United States
- Facility name not stated
New Brunswick, New Jersey, United States
- Facility name not stated
Albuquerque, New Mexico, United States
- Facility name not stated
New Hyde Park, New York, United States
- Facility name not stated
Chapel Hill, North Carolina, United States
- Facility name not stated
Akron, Ohio, United States
- Facility name not stated
Columbus, Ohio, United States
- Facility name not stated
Toledo, Ohio, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Hershey, Pennsylvania, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
- Facility name not stated
Pittsburgh, Pennsylvania, United States
- Facility name not stated
Charleston, South Carolina, United States
- Facility name not stated
Columbia, South Carolina, United States
- Facility name not stated
Richmond, Virginia, United States
- Facility name not stated
Morgantown, West Virginia, United States
- Facility name not stated
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2010
- Primary completion
- 30 Sept 2011
- Completion
- 31 Jan 2012
- Last update posted
- 11 Mar 2014
- Registered enrollment
- 102
- Registry id
- NCT01059565
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.